PhillyTablet Inquirer Daily News
philly.com
email
font size
options
 
Monday, March 9, 2009

"Merck expects to achieve substantial cost savings of approximately $3.5 billion annually beyond 2011" in its $41 billion purchase of Schering-Plough, Merck says in this release. "These cost savings are expected to come from all areas across the combined company and from the full integration of the Merck/Schering-Plough Pharmaceuticals cholesterol joint venture.  These cost savings are in addition to the previously announced ongoing cost reduction initiatives at both companies."

Bad news for North Jersey (like the Pfizer-Wyeth deal). Merck is based in Whitehouse Station, a little west of Newark; Schering-Plough in Kenilworth, about 25 miles further west on I-78. $3.5B is about one-third of Schering-Plough's yearly operating expenses (not counting, for example, the cost of drug materials) or 30% of Merck.

Meanwhile, Gov. Corzine and a majority of the New Jersey Senate want to legalize "medical" marijuana sales, sparking a pharmaceutical boom around the time mainstream pharma is in high consolidation. Just in time to replace pharma-merger job losses? Last year the New Yorker visited California's medical-marijuana clinics and marijuana farms, and described a heavily armed, paranoid industry where some doctors get rich writing pot prescriptions for anyone and sad, low-paid ex-hippies do the grunt work.

Posted by Joseph N. DiStefano @ 9:39 AM  Permalink | Post a comment
Comments   


0 comments
About Joseph N. DiStefano
Joseph N. DiStefano writes this blog to feed his PhillyDeals column in the Philadelphia Inquirer. Joe has been a member of Bloomberg LP’s New York Finance Team, wrote the book “Comcasted,” taught writing at St. Joseph’s University, and studied economics and history at Penn. Reach Joe at 215-854-5194 and JoeD@phillynews.com